芪倍合剂联合康复新液治疗对溃疡性结肠炎患者肠道菌群及APTT、IL-23的影响

目的分析芪倍合剂联合康复新液治疗对溃疡性结肠炎(UC)患者肠道菌群及活化部分凝血活酶时间(APTT)、白细胞介素(IL)-23的影响。方法将2017年1月至2018年11月100例UC患者随机分为观察组及对照组,对照组在常规治疗基础上口服芪倍合剂治疗,观察组在对照组基础上采用康复新液干预。治疗结束后对患者疗效进行评估,以及检测治疗后患者粪便球杆比,并对两组患者治疗前后APTT、纤维蛋白原(FIB)、IL-23、IL-17及肿瘤坏死因子(TNF)-α水平进行比较分析。结果观察组临床疗效及肠道菌群失调改善情况均显著优于对照组,差异有统计学意义(P<0.05);观察组治疗后APTT水平显著高于对照组,FIB、IL-23、IL-17及TNF-α水平显著低于对照组,差异有统计学意义(P<0.05)。结论采用芪倍合剂联合康复新液对UC患者治疗后可显著改善患者病情及肠道菌群,并显著降低患者血中FIB及IL-23水平。

Effect of Qibei mixture and Kangfuxin solution on intestinal microflora,APTT and IL-23 in patients with ulcerative colitis

Objective To analyze the effect of Qibei mixture combined with Kangfuxin liquid on intestinal flora,activated partial thromboplastin time(APTT)and interleukin-23(IL-23)in ulcerative colitis(UC)patients.Methods 100 UC patients were divided into observation group and control group randomly,from January 2017 to November 2018.The control group was treated with Qibei mixture on the basis of routine treatment,while the observation group was treated with Kangfuxin solution on the basis of control group.After the treatment,the therapeutic effect of the patients was evaluated,and the fecal ball-to-stick ratio of patients was measured after treatment;The levels of APTT,fibrinogen(FIB),IL-23,IL-17 and tumor necrosis factor-α(TNF-α)were compared before and after treatment.Results The clinical efficacy and improvement of intestinal flora imbalance in the observation group were significantly better than those in the control group,the difference was statistically significant(P<0.05);After treatment,the APTT level in the observation group was significantly higher than that in the control group,and the levels of FIB,IL-23,IL-17 and TNF-αwere significantly lower than those in the control group,the difference was statistically significant(P<0.05).Conclusion Qibei mixture combined with Kangfuxin solution can significantly improve the condition and intestinal flora of UC patients after treatment,and significantly reduce the levels of FIB and IL-23 in patients with UC.